Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Treasury Shares (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Treasury Shares for 6 consecutive years, with $306415.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 8.97% to $306415.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $306415.0 through Dec 2025, up 8.97% year-over-year, with the annual reading at $306415.0 for FY2025, 8.97% up from the prior year.
  • Treasury Shares hit $306415.0 in Q4 2025 for Lyell Immunopharma, down from $321498.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.1 million in Q1 2025 to a low of $281190.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $2.6 million across 5 years, with a median of $2.6 million in 2021.
  • Biggest five-year swings in Treasury Shares: skyrocketed 323.92% in 2021 and later crashed 92.62% in 2025.
  • Year by year, Treasury Shares stood at $2.6 million in 2021, then crashed by 66.46% to $872077.0 in 2022, then soared by 137.69% to $2.1 million in 2023, then plummeted by 86.43% to $281190.0 in 2024, then increased by 8.97% to $306415.0 in 2025.
  • Business Quant data shows Treasury Shares for LYEL at $306415.0 in Q4 2025, $321498.0 in Q3 2025, and $381671.0 in Q2 2025.